These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 21863672

  • 1. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
    Thongcharoen P, Auewarakul P, Hutagalung Y, Ong G, Gillard P, Drame M, Bock HL.
    J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
    [Abstract] [Full Text] [Related]

  • 2. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
    Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW, H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand.
    Vaccine; 2009 Dec 09; 27(52):7428-35. PubMed ID: 19683087
    [Abstract] [Full Text] [Related]

  • 4. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L.
    J Infect Dis; 2010 Jun 01; 201(11):1644-53. PubMed ID: 20423222
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.
    Pediatr Infect Dis J; 2010 Jun 01; 29(6):e35-46. PubMed ID: 20375709
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.
    Vaccine; 2012 Feb 08; 30(7):1388-96. PubMed ID: 22192847
    [Abstract] [Full Text] [Related]

  • 7. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.
    J Infect Dis; 2008 Sep 01; 198(5):642-9. PubMed ID: 18576945
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.
    Vaccine; 2015 Jun 04; 33(24):2800-7. PubMed ID: 25910919
    [Abstract] [Full Text] [Related]

  • 11. Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong.
    Chu DW, Kwong AS, Tsui WW, Wang JH, Ngai CK, Wan PK, Ong G, Tang HW, Roman F, Dram M, Bock HL.
    Hong Kong Med J; 2011 Feb 04; 17(1):39-46. PubMed ID: 21282825
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
    Hwang SJ, Chang SC, Yu CJ, Chan YJ, Chen TJ, Hsieh SL, Lai HY, Lin MH, Liu JY, Ong G, Roman F, Dramé M, Bock HL, Yang PC.
    J Formos Med Assoc; 2011 Dec 04; 110(12):780-6. PubMed ID: 22248833
    [Abstract] [Full Text] [Related]

  • 13. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
    Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.
    Vaccine; 2011 Feb 17; 29(9):1777-82. PubMed ID: 21216315
    [Abstract] [Full Text] [Related]

  • 14. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 15. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.
    Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.
    Vaccine; 2009 Dec 30; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [Abstract] [Full Text] [Related]

  • 18. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R, Amicizia D, Lai PL, Panatto D.
    Expert Rev Vaccines; 2012 Feb 30; 11(2):145-57. PubMed ID: 22309663
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
    Heldens JG, Glansbeek HL, Hilgers LA, Haenen B, Stittelaar KJ, Osterhaus AD, van den Bosch JF.
    Vaccine; 2010 Nov 29; 28(51):8125-31. PubMed ID: 20950729
    [Abstract] [Full Text] [Related]

  • 20. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.
    Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.